Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Impilo on the establishment of a continuation fund
Mandate

Vinge advises Impilo on the establishment of a continuation fund

November 15, 2024

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.

Impilo is a Nordic investment company specializing in investments within the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo holds a highly diversified portfolio of healthcare investments and manages approximately EUR 1 billion in capital, from leading Nordic and international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist and Viktoria Wnuk.

Related

Vinge has advised Bolero in connection with sale of shares in Ambea AB (publ)

 Vinge has advised Bolero Holdings S.à r.l. in connection with the sale of shares in Ambea AB (publ) through an accelerated bookbuilding process carried out on 1 December 2025.
December 02, 2025

Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million

 Vinge has advised the property company Intea Fastigheter AB (publ) in connection with a directed share issue of shares of series D through which the company raises proceeds of approximately SEK 500 million before transaction costs. A part of the share issue is subject to subsequent approval at an extraordinary general meeting.
December 01, 2025

Vinge advises on the sale of Kaelus to Baylin Technologies

 Baylin Technologies, listed on the Toronto Stock Exchange, has entered into an agreement to acquire all shares in the Swedish company, Kaelus for approximately SEK 285 million with the aim of creating a global leader in wireless technology.
December 01, 2025